Curcumin has been testified to repress the development of multiple tumor cells. Nevertheless, the function of curcumin in colorectal cancer (CRC) is not completely clarified. This research was to explore the influence of curcumin on the development of CRC cells and its mechanism. An examination of circular RNA (circ) HN1, microRNA (miR)-302a-3p and phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) levels in clinical tissues was performed. Assessments of cell development including proliferation, apoptosis, migration, invasion, as well as epithelial-mesenchymal transition were conducted. The effects of curcumin and circHN1 were verified by in vivo tumor implantation experiments. The interaction of miR-302a-3p with circHN1 or PIK3R3 was analyzed. Curcumin repressed CRC cell development in a concentration-dependent manner. CircHN1 expression was augmented in CRC. Augmentation of circHN1 was able to turn around the repressive effects of curcumin on CRC cells. In vivo experiments indicated that low expression of circHN1 further promoted curcumin-mediated inhibition of CRC tumor growth. MiR-302a-3p was a target of circHN1, and suppression of miR-302a-3p was able to turn around the treatment effect of curcumin on CRC cells. Additionally, PIK3R3 was targeted by miR-302a-3p, and curcumin modulated the malignancy of CRC cells through the circHN1/miR-302a-3p/PIK3R3 pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26402/jpp.2022.2.05 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism Analysis of the Effect of Cordycepin on Colorectal Cancer via Network Pharmacology and Experiment.
Comb Chem High Throughput Screen
January 2025
Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Objective: Colorectal Cancer (CRC) has attracted much attention due to its high mortality and morbidity. Cordycepin, also known as 3'-deoxyadenosine (3'-dA), exhibits many biological functions, including antibacterial, anti-inflammatory, antiviral, anti-tumor, and immunomodulatory effects. It has been proven to show anticancer activity in both laboratory research studies and living organisms.
View Article and Find Full Text PDFNew Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite Stable Colorectal Cancer Metastasis in Combination with Immune Checkpoint Therapy in Mice.
ACS Pharmacol Transl Sci
January 2025
Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10, Barcelona 08028, Spain.
Blockade of the TGFβ signaling pathway has emerged from preclinical studies as a potential treatment to enhance the efficacy of immune checkpoint inhibition in advanced colorectal cancer (CRC) and several other types of cancer. However, clinical translation of first-generation inhibitors has shown little success. Here, we report the synthesis and characterization of HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5), that is approximately 9 times more efficacious than the structurally related compound galunisertib, while maintaining a favorable safety profile.
View Article and Find Full Text PDFTargeting KAT7 inhibits the progression of colorectal cancer.
Theranostics
January 2025
Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Colorectal cancer (CRC) is a leading cause of cancer-related mortality. Epigenetic modifications play a significant role in the progression of CRC. KAT7, a histone acetyltransferase, has an unclear role in CRC.
View Article and Find Full Text PDFEstablishing a standardized murine orthotopic intra-rectal model for the study of colorectal adenocarcinoma.
J Gastrointest Oncol
December 2024
Medical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Background: Orthotopic models offer a more accurate representation of colorectal cancer (CRC) compared to subcutaneous models. Despite promising results from the reported intra-rectal models, establishing a standardized method for CRC research remains challenging due to model variability, hindering comprehensive studies on CRC pathogenesis and treatment modalities, such as brachytherapy. This study aimed to establish a standardized workflow for an orthotopic intra-rectal animal model to induce the growth of colorectal adenocarcinoma in male and female mice.
View Article and Find Full Text PDFLeptin increases chemosensitivity by inhibiting in colorectal cancer cells.
J Gastrointest Oncol
December 2024
Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Chemoresistance is a major cause of treatment failure in advanced colorectal cancer (CRC), severely impacting patient survival and quality of life. While conventional chemotherapy regimens can somewhat control tumor progression, their effectiveness is frequently compromised by the development of drug resistance in cancer cells. The aim of this study is to verify and elucidate the specific mechanisms by which leptin enhances chemosensitivity in CRC, providing valuable insights for the development of new combination chemotherapy options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!